Figs vs BioLife Solutions: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Figs Inc (FIGS)

Q3 202624 Jul – 28 Sep 2026

▲3

FIGS raises 2026 outlook on strong Q2 and international surge

FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.
This is the core new event that directly drives the stock higher.
International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.
Shows a key new growth driver that justifies the raised outlook.
Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.
New analyst actions and cash flow metrics that influence investor perception.
Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.
A new regulatory risk that could hurt supply, but with limited impact.

August 202624 Jul – 28 Sep 2026

▲3

FIGS raises 2026 outlook on strong Q2 and international surge

FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.
This is the core new event that directly drives the stock higher.
International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.
Shows a key new growth driver that justifies the raised outlook.
Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.
New analyst actions and cash flow metrics that influence investor perception.
Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.
A new regulatory risk that could hurt supply, but with limited impact.

Latest24 Jul – 28 Sep 2026

▲3

FIGS raises 2026 outlook on strong Q2 and international surge

FIGS raises 2026 revenue and margin outlook after strong Q2 FIGS lifted its 2026 revenue growth forecast to about 20% from 14-16% and operating margin target to roughly 10.8%. Q2 revenue jumped 29% to $196.6 million, with active customers up 13% to 3.1 million. This positive guidance signals confidence and growth, pushing the stock up.
This is the core new event that directly drives the stock higher.
International revenue surges 67%, expansion to 85 markets International revenue jumped 67% to $37.9 million, now 19% of total sales. FIGS expanded to 85 markets, adding 27 since year-end, and signed a partnership with Bupa Dental Care for nearly 400 UK dental centers. This broadens growth beyond the U.S., supporting the stock.
Shows a key new growth driver that justifies the raised outlook.
Analyst upgrades and strong cash flow boost sentiment After Q2 earnings beat, Barclays and KeyBanc raised price targets to $20, implying 36% upside. FIGS generated $97 million in free cash flow over the past year and trades at 22 times that, which some see as cheap. Upgrades and cash generation attract buyers, lifting the stock.
New analyst actions and cash flow metrics that influence investor perception.
Customs order blocks Jordan imports, but impact mitigated A U.S. Customs withhold release order blocks imports from FIGS' Jordan partner. Management says it has shifted production to other partners, mitigating most of the impact. While a risk, the mitigation limits the negative effect on the stock.
A new regulatory risk that could hurt supply, but with limited impact.

BioLife Solutions Inc (BLFS)

Q3 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

August 202622 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.

Latest22 Jul – 5 Oct 2026

▲2▼2

Repligen's $1.5B buyout locks BLFS to deal terms, not its own news

Repligen agrees to buy BioLife for $1.5 billion Repligen will pay $31 a share — $11.25 cash plus Repligen stock — a 24% premium to BioLife's recent average price. That buyout price now acts like a magnet for the stock: it trades near the deal value, and shareholders get cash plus Repligen shares when it closes.
The acquisition is the single force now setting BLFS's price.
Q2 beat shows the underlying business was healthy BioLife earned $0.04 a share versus an expected small loss, with revenue of $28.5 million, up about 21% from a year earlier and above forecasts — its fourth straight beat. Strong results support the deal price and make the buyer's case easier.
Shows the company's own performance still matters as a backstop to the deal.
Law firm probes whether the sale price is fair Investor-rights firm Halper Sadeh is investigating whether BioLife's board got shareholders a fair deal in the Repligen sale. Such reviews are common and often lead nowhere, but they can delay closing or pressure the buyer to raise its offer.
A real counterweight that could change deal terms or timing.
Removed from the S&P SmallCap 600 index BioLife is being dropped from the S&P SmallCap 600 and replaced by Freshworks, because it is being acquired. Index funds that tracked it must sell, but with the buyout nearly done, this mostly reflects the deal closing rather than new weakness.
Explains the forced selling around the deal's completion.